Alpha Lipoic Acid for Nerve Symptoms: SYDNEY 2, NATHAN 1 and the 600 mg Line

01Second in the blend, first in the evidence file

On the Quiet Nerves panel, alpha lipoic acid appears immediately after magnesium glycinate in the 575 mg proprietary blend.^[1] Federal labeling rules require the ingredients of a blend to be listed in descending order of weight, so that position tells us it is the second-heaviest component and nothing more precise than that.^[2] No milligram figure is printed for it.

The seller describes it as "a rare antioxidant that is both water- and fat-soluble" that "supports healthy nerve function".^[3] Of the six ingredients, this is the one with the deepest clinical record for nerve symptoms, which makes it the natural place to test the seller's FAQ statement that the formula uses "clinically effective doses". Alpha lipoic acid (also sold as thioctic acid, and abbreviated ALA below) has been through large randomized trials. Their doses are known. The question is how far one capsule sits from them.

A caveat before the data: almost every trial enrolled people with diabetic polyneuropathy, nerve damage caused by long-standing high blood sugar. Results in that group do not automatically carry over to tingling from other causes, a point we return to in symptoms that need a doctor.

02Infusions came first, capsules second

The early positive results came from intravenous dosing. A meta-analysis covering 1,258 patients found that 600 mg a day by infusion for three weeks improved neuropathy symptom scores more than placebo.^[4] An infusion places the whole dose in the bloodstream, which a capsule cannot do, so the oral trials are the relevant ones for a supplement.

SYDNEY 2 is the trial most often quoted in favor of oral ALA. It randomized 181 patients to placebo or to one of three daily doses for five weeks. All three active groups reported lower symptom scores than placebo, and because side effects were more frequent at the higher doses, the investigators judged 600 mg once daily to offer the best balance of benefit and risk.^[5]

The two longer trials are less flattering. ALADIN III followed 509 patients through a course of infusions and then six months of 1,800 mg a day by mouth, and found no significant difference from placebo on the symptom score.^[6] NATHAN 1 gave 600 mg a day for four years to 460 patients with diabetic polyneuropathy. Its primary endpoint, a composite of an examination score and nerve function tests, was not met, although some measures of neuropathic deficits favored ALA.^[7]

03How the pooled reviews read the same trials

Reviewers who pooled these studies reached conclusions that became more cautious over time. A 2012 meta-analysis of four randomized trials with 653 patients judged the benefit of intravenous treatment clinically relevant and the benefit of oral treatment unclear.^[8] An expert review of ALA efficacy published two years later was co-written by the lead investigator of the main trials, a relationship worth keeping in mind when weighing it.^[9]

The most recent and most rigorous assessment is the 2024 Cochrane review, which concluded that oral ALA probably makes little or no difference to neuropathy symptoms at six months compared with placebo.^[10] That is a statement about 600 mg and above, taken daily for half a year.

04The 600 mg line and the capsule

Now the arithmetic. The label prints 80 mg of magnesium "from proprietary blend", and magnesium is 14.1% of fully reacted magnesium glycinate by weight. Supplying 80 mg therefore takes about 567 mg of glycinate, which leaves about 8 mg of the 575 mg blend for the remaining five ingredients together. ALA is the first of those five, so its ceiling is that whole remainder.

These numbers are label math under stated assumptions, not a laboratory result; no capsule was sent for analysis, and the seller could settle the question by printing the amount. What the arithmetic does establish is a boundary. Under the reading most favorable to the product, one capsule cannot contain more than about a fifth of the lowest dose tested in SYDNEY 2, and under the plain reading of "magnesium glycinate" it contains barely more than a hundredth. The full derivation, including why descending order fixes each ceiling, is in the 575 mg blend, solved, and the ingredients page covers all six actives side by side.

05Half-life, food and the "with a meal" instruction

Pharmacokinetic work in healthy volunteers shows that oral ALA is absorbed quickly and cleared quickly, with a short plasma half-life.^[13] A study of the two mirror-image forms of the molecule (its enantiomers) found that food intake lowered bioavailability, which is why trial protocols typically scheduled the dose before a meal.^[14]

The Quiet Nerves label says only "take one (1) capsule daily". The seller's FAQ adds "with a meal and a full glass of water".^[1,3] For magnesium that advice is reasonable, since food tends to soften any stomach upset. For ALA it is the opposite of how the trials were run. At a ceiling of a few milligrams the difference is academic, but it is one more sign that the instructions were not written around this ingredient's research.

06Blood sugar and a rare immune reaction

ALA has measurable metabolic effects at research doses. A meta-analysis of randomized trials found modest reductions in fasting glucose and HbA1c, and a six-month trial in people with type 2 diabetes saw a dose-related downward trend in glucose across 300 to 1,200 mg a day.^[15,16] For someone using insulin or another glucose-lowering medicine, anything that lowers glucose further is a reason to monitor more closely.

There is also a rare reaction worth knowing by name. Insulin autoimmune syndrome is a condition in which the body makes antibodies against its own insulin, causing episodes of low blood sugar. Reviews list ALA among the sulfur-containing compounds that can trigger it in susceptible people, and individual cases in ALA users have been published.^[17,18]

07What a careful reader can take from the ALA file

Three statements survive the evidence. First, the positive oral result for ALA is short term, at 600 mg a day, in diabetic polyneuropathy. Second, longer trials and the latest Cochrane review are lukewarm even at that dose. Third, the Quiet Nerves label caps ALA at somewhere between about 8 mg and about 131 mg, so the capsule cannot reproduce any of the trials above.

None of this makes the ingredient unsafe at the label amount; small doses are the least likely to cause the side effects that rose with dose in SYDNEY 2. It does mean ALA's research cannot be borrowed to describe this product. The same test applied to the next ingredient is in L-carnitine vs acetyl-L-carnitine. Readers who have weighed this and still wish to try the capsule can go to the seller's 6-bottle order page at $49 a bottle; we may earn a commission, and the 60-day refund reading is on our refund steps page.